Cargando…
Pharmacogenomics of MDD as a Developing Field: Challenges and Opportunities
While first gene-drug pairs have emerged to be clinically actionable in the treatment of major depressive disorders (MDD) (e.g., CYP2D6 and TCAs/SSRIs), genomic studies have not yet been successful in identifying replicable and valid biomarkers of pharmacological treatment outcome. While some trials...
Autor principal: | Baune, B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562755/ http://dx.doi.org/10.1192/j.eurpsy.2022.136 |
Ejemplares similares
-
Challenges and Opportunities in Pharmacogenomics and Therapeutics
por: Kane, Michael D., et al.
Publicado: (2007) -
Opportunities and challenges of implementing Pharmacogenomics in cancer drug development
por: Tarantino, Paolo, et al.
Publicado: (2019) -
Why is Diagnosing MDD Challenging?
Publicado: (2016) -
Current challenges and opportunities for pharmacogenomics: perspective of the Industry Pharmacogenomics Working Group (I-PWG)
por: Bienfait, Karina, et al.
Publicado: (2021) -
Polygenic risk scores in pharmacogenomics: opportunities and challenges—a mini review
por: Simona, Aurélien, et al.
Publicado: (2023)